Loading…

Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences: A Practical Approach

Anticoagulation therapy is the standard treatment of patients with symptomatic venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Until recently, treatment of VTE was based on parenteral or low-molecular-weight heparin for initial therapy (5-10 days) and oral vitami...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and applied thrombosis/hemostasis 2015-05, Vol.21 (4), p.297-308
Main Authors: Arcelus, Juan I., Domènech, Pere, Fernández-Capitan, Ma del Carmen, Guijarro, Ricardo, Jiménez, David, Jiménez, Sonia, Lozano, Francisco S., Monreal, Manel, Nieto, José A., Páramo, José A.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c290t-abb52dd138546e7cdcf0aa8d0c043e18e9c39c9f95ab7399745c48077d7a396a3
container_end_page 308
container_issue 4
container_start_page 297
container_title Clinical and applied thrombosis/hemostasis
container_volume 21
creator Arcelus, Juan I.
Domènech, Pere
Fernández-Capitan, Ma del Carmen
Guijarro, Ricardo
Jiménez, David
Jiménez, Sonia
Lozano, Francisco S.
Monreal, Manel
Nieto, José A.
Páramo, José A.
description Anticoagulation therapy is the standard treatment of patients with symptomatic venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Until recently, treatment of VTE was based on parenteral or low-molecular-weight heparin for initial therapy (5-10 days) and oral vitamin K antagonists for long-term therapy. Those treatments have some limitations, including parenteral administration (heparins), the need for frequent monitoring and dose adjustments, interactions with several medications, and dietary restrictions (vitamin K antagonists). Rivaroxaban is a new oral direct factor Xa inhibitor with a wide therapeutic window, predictable anticoagulant effect, no food interactions, and few drug interactions. Consequently, no periodic monitoring of anticoagulation is needed, and fixed doses can be prescribed. EINSTEIN program demonstrated that rivaroxaban was as effective as and significantly safer than standard therapy for treatment of VTE. Rivaroxaban was recently authorized so doubts exist about how to use it in daily clinical practice. This document aims to clarify common questions formulated by clinicians regarding the use of this new drug.
doi_str_mv 10.1177/1076029614561321
format article
fullrecord <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_1668240636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1076029614561321</sage_id><sourcerecordid>1668240636</sourcerecordid><originalsourceid>FETCH-LOGICAL-c290t-abb52dd138546e7cdcf0aa8d0c043e18e9c39c9f95ab7399745c48077d7a396a3</originalsourceid><addsrcrecordid>eNp1kM1LxDAQxYMo7rp69yQ9eqnmo02aoyx-wYKyrOKtpMnU7dIma9Iu-t-bddWD4GGYgfebx8xD6JTgC0KEuCRYcEwlJ1nOCaNkD42JZEVKBWX7cY5yutVH6CiEFcZEcskP0YjmOc6klGP0Mm82yrt3VSmbNDbpl5AsPKi-A9snrk6ewbohJIuld13lIFbbhC5R1nyxjx42kWyc3cJz0IP3YDWEY3RQqzbAyXefoKeb68X0Lp093N5Pr2apphL3qaqqnBpDWJFnHIQ2usZKFQZrnDEgBUjNpJa1zFUlmJQiy3VWYCGMUExyxSbofOe79u5tgNCXXRM0tK2yEA8vCecFzTBnPKJ4h2rvQvBQl2vfdMp_lASX2zzLv3nGlbNv96HqwPwu_AQYgXQHBPUK5coN3sZv_zf8BDokfXQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1668240636</pqid></control><display><type>article</type><title>Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences: A Practical Approach</title><source>SAGE Open Access</source><creator>Arcelus, Juan I. ; Domènech, Pere ; Fernández-Capitan, Ma del Carmen ; Guijarro, Ricardo ; Jiménez, David ; Jiménez, Sonia ; Lozano, Francisco S. ; Monreal, Manel ; Nieto, José A. ; Páramo, José A.</creator><creatorcontrib>Arcelus, Juan I. ; Domènech, Pere ; Fernández-Capitan, Ma del Carmen ; Guijarro, Ricardo ; Jiménez, David ; Jiménez, Sonia ; Lozano, Francisco S. ; Monreal, Manel ; Nieto, José A. ; Páramo, José A.</creatorcontrib><description>Anticoagulation therapy is the standard treatment of patients with symptomatic venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Until recently, treatment of VTE was based on parenteral or low-molecular-weight heparin for initial therapy (5-10 days) and oral vitamin K antagonists for long-term therapy. Those treatments have some limitations, including parenteral administration (heparins), the need for frequent monitoring and dose adjustments, interactions with several medications, and dietary restrictions (vitamin K antagonists). Rivaroxaban is a new oral direct factor Xa inhibitor with a wide therapeutic window, predictable anticoagulant effect, no food interactions, and few drug interactions. Consequently, no periodic monitoring of anticoagulation is needed, and fixed doses can be prescribed. EINSTEIN program demonstrated that rivaroxaban was as effective as and significantly safer than standard therapy for treatment of VTE. Rivaroxaban was recently authorized so doubts exist about how to use it in daily clinical practice. This document aims to clarify common questions formulated by clinicians regarding the use of this new drug.</description><identifier>ISSN: 1076-0296</identifier><identifier>EISSN: 1938-2723</identifier><identifier>DOI: 10.1177/1076029614561321</identifier><identifier>PMID: 25504999</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Drug Interactions ; Drug Monitoring ; Factor Xa Inhibitors - pharmacokinetics ; Factor Xa Inhibitors - therapeutic use ; Humans ; Recurrence ; Rivaroxaban - pharmacokinetics ; Rivaroxaban - therapeutic use ; Venous Thromboembolism - blood ; Venous Thromboembolism - prevention &amp; control</subject><ispartof>Clinical and applied thrombosis/hemostasis, 2015-05, Vol.21 (4), p.297-308</ispartof><rights>The Author(s) 2014</rights><rights>The Author(s) 2014.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c290t-abb52dd138546e7cdcf0aa8d0c043e18e9c39c9f95ab7399745c48077d7a396a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1076029614561321$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1076029614561321$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21966,27853,27924,27925,37013,44945,45333</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/1076029614561321?utm_source=summon&amp;utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25504999$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Arcelus, Juan I.</creatorcontrib><creatorcontrib>Domènech, Pere</creatorcontrib><creatorcontrib>Fernández-Capitan, Ma del Carmen</creatorcontrib><creatorcontrib>Guijarro, Ricardo</creatorcontrib><creatorcontrib>Jiménez, David</creatorcontrib><creatorcontrib>Jiménez, Sonia</creatorcontrib><creatorcontrib>Lozano, Francisco S.</creatorcontrib><creatorcontrib>Monreal, Manel</creatorcontrib><creatorcontrib>Nieto, José A.</creatorcontrib><creatorcontrib>Páramo, José A.</creatorcontrib><title>Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences: A Practical Approach</title><title>Clinical and applied thrombosis/hemostasis</title><addtitle>Clin Appl Thromb Hemost</addtitle><description>Anticoagulation therapy is the standard treatment of patients with symptomatic venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Until recently, treatment of VTE was based on parenteral or low-molecular-weight heparin for initial therapy (5-10 days) and oral vitamin K antagonists for long-term therapy. Those treatments have some limitations, including parenteral administration (heparins), the need for frequent monitoring and dose adjustments, interactions with several medications, and dietary restrictions (vitamin K antagonists). Rivaroxaban is a new oral direct factor Xa inhibitor with a wide therapeutic window, predictable anticoagulant effect, no food interactions, and few drug interactions. Consequently, no periodic monitoring of anticoagulation is needed, and fixed doses can be prescribed. EINSTEIN program demonstrated that rivaroxaban was as effective as and significantly safer than standard therapy for treatment of VTE. Rivaroxaban was recently authorized so doubts exist about how to use it in daily clinical practice. This document aims to clarify common questions formulated by clinicians regarding the use of this new drug.</description><subject>Drug Interactions</subject><subject>Drug Monitoring</subject><subject>Factor Xa Inhibitors - pharmacokinetics</subject><subject>Factor Xa Inhibitors - therapeutic use</subject><subject>Humans</subject><subject>Recurrence</subject><subject>Rivaroxaban - pharmacokinetics</subject><subject>Rivaroxaban - therapeutic use</subject><subject>Venous Thromboembolism - blood</subject><subject>Venous Thromboembolism - prevention &amp; control</subject><issn>1076-0296</issn><issn>1938-2723</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kM1LxDAQxYMo7rp69yQ9eqnmo02aoyx-wYKyrOKtpMnU7dIma9Iu-t-bddWD4GGYgfebx8xD6JTgC0KEuCRYcEwlJ1nOCaNkD42JZEVKBWX7cY5yutVH6CiEFcZEcskP0YjmOc6klGP0Mm82yrt3VSmbNDbpl5AsPKi-A9snrk6ewbohJIuld13lIFbbhC5R1nyxjx42kWyc3cJz0IP3YDWEY3RQqzbAyXefoKeb68X0Lp093N5Pr2apphL3qaqqnBpDWJFnHIQ2usZKFQZrnDEgBUjNpJa1zFUlmJQiy3VWYCGMUExyxSbofOe79u5tgNCXXRM0tK2yEA8vCecFzTBnPKJ4h2rvQvBQl2vfdMp_lASX2zzLv3nGlbNv96HqwPwu_AQYgXQHBPUK5coN3sZv_zf8BDokfXQ</recordid><startdate>201505</startdate><enddate>201505</enddate><creator>Arcelus, Juan I.</creator><creator>Domènech, Pere</creator><creator>Fernández-Capitan, Ma del Carmen</creator><creator>Guijarro, Ricardo</creator><creator>Jiménez, David</creator><creator>Jiménez, Sonia</creator><creator>Lozano, Francisco S.</creator><creator>Monreal, Manel</creator><creator>Nieto, José A.</creator><creator>Páramo, José A.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201505</creationdate><title>Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences</title><author>Arcelus, Juan I. ; Domènech, Pere ; Fernández-Capitan, Ma del Carmen ; Guijarro, Ricardo ; Jiménez, David ; Jiménez, Sonia ; Lozano, Francisco S. ; Monreal, Manel ; Nieto, José A. ; Páramo, José A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c290t-abb52dd138546e7cdcf0aa8d0c043e18e9c39c9f95ab7399745c48077d7a396a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Drug Interactions</topic><topic>Drug Monitoring</topic><topic>Factor Xa Inhibitors - pharmacokinetics</topic><topic>Factor Xa Inhibitors - therapeutic use</topic><topic>Humans</topic><topic>Recurrence</topic><topic>Rivaroxaban - pharmacokinetics</topic><topic>Rivaroxaban - therapeutic use</topic><topic>Venous Thromboembolism - blood</topic><topic>Venous Thromboembolism - prevention &amp; control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arcelus, Juan I.</creatorcontrib><creatorcontrib>Domènech, Pere</creatorcontrib><creatorcontrib>Fernández-Capitan, Ma del Carmen</creatorcontrib><creatorcontrib>Guijarro, Ricardo</creatorcontrib><creatorcontrib>Jiménez, David</creatorcontrib><creatorcontrib>Jiménez, Sonia</creatorcontrib><creatorcontrib>Lozano, Francisco S.</creatorcontrib><creatorcontrib>Monreal, Manel</creatorcontrib><creatorcontrib>Nieto, José A.</creatorcontrib><creatorcontrib>Páramo, José A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and applied thrombosis/hemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Arcelus, Juan I.</au><au>Domènech, Pere</au><au>Fernández-Capitan, Ma del Carmen</au><au>Guijarro, Ricardo</au><au>Jiménez, David</au><au>Jiménez, Sonia</au><au>Lozano, Francisco S.</au><au>Monreal, Manel</au><au>Nieto, José A.</au><au>Páramo, José A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences: A Practical Approach</atitle><jtitle>Clinical and applied thrombosis/hemostasis</jtitle><addtitle>Clin Appl Thromb Hemost</addtitle><date>2015-05</date><risdate>2015</risdate><volume>21</volume><issue>4</issue><spage>297</spage><epage>308</epage><pages>297-308</pages><issn>1076-0296</issn><eissn>1938-2723</eissn><abstract>Anticoagulation therapy is the standard treatment of patients with symptomatic venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism. Until recently, treatment of VTE was based on parenteral or low-molecular-weight heparin for initial therapy (5-10 days) and oral vitamin K antagonists for long-term therapy. Those treatments have some limitations, including parenteral administration (heparins), the need for frequent monitoring and dose adjustments, interactions with several medications, and dietary restrictions (vitamin K antagonists). Rivaroxaban is a new oral direct factor Xa inhibitor with a wide therapeutic window, predictable anticoagulant effect, no food interactions, and few drug interactions. Consequently, no periodic monitoring of anticoagulation is needed, and fixed doses can be prescribed. EINSTEIN program demonstrated that rivaroxaban was as effective as and significantly safer than standard therapy for treatment of VTE. Rivaroxaban was recently authorized so doubts exist about how to use it in daily clinical practice. This document aims to clarify common questions formulated by clinicians regarding the use of this new drug.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>25504999</pmid><doi>10.1177/1076029614561321</doi><tpages>12</tpages></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 1076-0296
ispartof Clinical and applied thrombosis/hemostasis, 2015-05, Vol.21 (4), p.297-308
issn 1076-0296
1938-2723
language eng
recordid cdi_proquest_miscellaneous_1668240636
source SAGE Open Access
subjects Drug Interactions
Drug Monitoring
Factor Xa Inhibitors - pharmacokinetics
Factor Xa Inhibitors - therapeutic use
Humans
Recurrence
Rivaroxaban - pharmacokinetics
Rivaroxaban - therapeutic use
Venous Thromboembolism - blood
Venous Thromboembolism - prevention & control
title Rivaroxaban in the Treatment of Venous Thromboembolism and the Prevention of Recurrences: A Practical Approach
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A50%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rivaroxaban%20in%20the%20Treatment%20of%20Venous%20Thromboembolism%20and%20the%20Prevention%20of%20Recurrences:%20A%20Practical%20Approach&rft.jtitle=Clinical%20and%20applied%20thrombosis/hemostasis&rft.au=Arcelus,%20Juan%20I.&rft.date=2015-05&rft.volume=21&rft.issue=4&rft.spage=297&rft.epage=308&rft.pages=297-308&rft.issn=1076-0296&rft.eissn=1938-2723&rft_id=info:doi/10.1177/1076029614561321&rft_dat=%3Cproquest_AFRWT%3E1668240636%3C/proquest_AFRWT%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c290t-abb52dd138546e7cdcf0aa8d0c043e18e9c39c9f95ab7399745c48077d7a396a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1668240636&rft_id=info:pmid/25504999&rft_sage_id=10.1177_1076029614561321&rfr_iscdi=true